Author

H. V. Patel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

A. B. Cognetta· 1 shared A. Dayoub· 1 shared A. E. Smith· 1 shared A. Gasco Hernandez· 1 shared A. Ho· 1 shared A. McCloskey· 1 shared A. Saunders· 1 shared B. B. Aldridge· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. B. Cognetta

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity

A. E. Smith, S. Chan, Z. Wang, A. McCloskey, Q. Reilly, J. Z. Wang, H. V. Patel, K. Koshizuka, H. S. Soifer, L. Kessler, A. Dayoub, V. Villaflor, D. Adkins, J. Y. Bruce, A. Ho, , S. Malik

This study combines tipifarnib and alpelisib to target PI3K-mTOR and HRAS in HNSCC, showing synergy in mTOR inhibition and clinical potential for R/M HNSCC patients.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology

A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis

M. Li, H. V. Patel, A. B. Cognetta, T. C. Smith, B. B. Aldridge, I. Mallick, J.-F. Cavalier, T. C. Smith, B. F. Cravatt, J. C. Seeliger

This study uses ABPP to identify cell wall synthesis inhibitors targeting Mycobacterium tuberculosis, showing that active compounds inhibit serine hydrolases involved in cell wall and lipid metabolism.

bioRxiv · Apr 16, 2021Microbiology